In a significant advancement for melanoma treatment, the phase 2 SWOG S1512 trial demonstrated that neoadjuvant pembrolizumab, an anti-PD-1 therapy, achieved a remarkable 71% pathological complete response rate in patients with resectable desmoplastic melanoma. This promising finding highlights the drug’s potential in effectively targeting this aggressive subtype of melanoma.
The trial specifically aimed to evaluate the response to pembrolizumab among individuals with surgical candidates for desmoplastic melanoma. In cohort A, 28 eligible patients received pembrolizumab intravenously at a dosage of 200 mg every three weeks for three cycles before undergoing surgical excision. Pathological evaluations were conducted at baseline, three to five weeks post-treatment initiation, and once more at the time of surgery to assess the treatment’s efficacy.
The primary endpoint, the pathological complete response rate assessed through local pathological review, yielded impressive results: a 71% response rate with a 95% confidence interval of 51–87 (P < 0.001). This achievement significantly surpasses expectations, illustrating pembrolizumab’s effectiveness in prompting substantial tumor responses in this patient population.
In addition to focusing on the primary endpoint, the trial also evaluated secondary outcomes, including clinical response rates and overall survival, with follow-up extending to three years. Such comprehensive tracking allows for preliminary insights into longer-term outcomes for patients with resectable desmoplastic melanoma.
Survivorship at the three-year mark reported that four participants had passed away; however, none of the deaths were directly linked to melanoma or treatment-related adverse events. This statistic is particularly significant as it contextualizes the longer-term safety and efficacy of neoadjuvant pembrolizumab for these patients.
Overall, the treatment was generally well tolerated, with only two patients experiencing grade 3 treatment-related adverse events, accounting for 7% of the study cohort. Notably, no additional high-grade toxicities were documented, underscoring the manageable safety profile of the therapy.
These findings underscore the favorable efficacy and safety characteristics of neoadjuvant pembrolizumab among patients with resectable desmoplastic melanoma. Given the high pathological complete response rate and acceptable safety profile, these results support the case for further exploration of neoadjuvant PD-1 blockade in this unique melanoma subtype.
The study, conducted by Kendra KL et al., marks a pivotal moment in the ongoing search for effective therapies against challenging melanoma variants and may pave the way for improved outcomes among those affected by this disease.
For more information, refer to the original study published in Nature Cancer (2026) at https://doi.org/10.1038/s43018-025-01113-y.
Categories: Melanoma, Oncology, Immunotherapy
Tags: Pembrolizumab, Desmoplastic Melanoma, Neoadjuvant Therapy, SWOG S1512, Cancer Research
Original Source: https://www.emjreviews.com/oncology/news/high-complete-response-rate-with-neoadjuvant-pembrolizumab/
Category :
Tags:
Publish Date: 2026-02-14 17:33:00
